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Background: Hydroxychloroquine (HCQ) is currently being examined for COVID-19. No 
previous meta-analysis has evaluated its side effects versus placebo. We conducted this meta-
analysis to compare the safety of HCQ versus placebo. 
Methods: Two authors independently searched PubMed and EMBASE databases for 
randomized controlled trials (RCTs) of adults comparing the adverse events (AEs) of HCQ 
versus placebo for any indication. Peto odds ratios (Peto ORs) and 95% confidence intervals 
(CIs) were calculated based on random-effects models. The heterogeneity (I2) was assessed using 
Cochran’s Q test. 
Results: Nine RCTs (eight were double-blind) with a total of 916 patients were included. HCQ 
caused significantly more skin pigmentation than placebo (Peto OR, 4.64; 95% CI, 1.13 to 19.00; 
P-value=0.033; I2=0%). The increase in other AEs did not reach statistical significance: rash
(Peto OR, 1.11; 95% CI, 0.3 to 3.77; P-value=0.03; I2=0%); gastrointestinal AEs (Peto OR, 1.43; 
95% CI, 0.55 to 3.72; P-value=0.46; I2=15.17%); headache (Peto OR, 1.94; 95% CI, 0.65 to 
5.78; P-value=0.23; I2=9.99%); dizziness (Peto OR, 1.32; 95% CI, 0.49 to 3.52; P-value=0.58; 
I2=0%); fatigue (Peto OR, 2.13; 95% CI, 0.76 to 5.98; P-value=0.15; I2=0%); and visual AEs 
(Peto OR, 1.61; 95% CI, 0.76 to 3.41; P-value=0.22; I2=0%). Cardiac toxicity was not reported. 
Conclusions: This meta-analysis of RCTs found a significantly higher risk of skin pigmentation 
in HCQ users versus placebo. More data are needed to evaluate HCQ in the context of COVID-
19 treatment. 
INTRODUCTION 
The 4-aminoquinoline compounds such as chloroquine (CQ) and its hydroxylated analog, 
hydroxychloroquine (HCQ), have been widely used in the treatment of malaria [1]. Additionally, 
HCQ is an approved treatment for a number of autoimmune diseases such as systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA) [2]. Further observations highlight its 
potential efficacy in a wide range of conditions, including endocrine diseases, coagulopathies, 
and infectious diseases [3]. Due to its lower toxicity, HCQ is preferred over CQ in rheumatic 
conditions. The definite mechanism of action of HCQ in controlling these diseases is unknown. 
HCQ is thought to work by interfering with lysosomal activity, inhibition presentation of 
antigens and Tolllike receptor signaling, and termination of circulating immune complexes [4]. 
HCQ has a very long half-life due to extensive tissue uptake. It is available only in oral dosage 
forms and needs to be taken with food to reduce the risk of gastrointestinal adverse reactions [2]. 
Since there is no specific approved therapy for Coronavirus Disease 2019 (COVID-19) 
yet, multiple agents with antiviral activity are being used as possible therapies such as HCQ, CQ, 
remdesivir, and lopinavir-retonavir [5, 6, 7, 8]. In addition to its immunomodulatory effects, 
HCQ has some antiviral activity [6]. Despite being a relatively safe and low-cost drug, HCQ can 
cause a number of side effects and its toxicity is not well understood, partially due to the limited 
number of patients (low statistical power) in the published randomized controlled trials (RCTs). 
Therefore, it is useful to conduct this first meta-analysis pooling of all data on its adverse 
reactions to better understand its safety compared to placebo. The objective of this study is to 
compare the side effects of HCQ to placebo through a meta-analysis of RCTs of adults who 
received hydroxychloroquine. 
    
 
METHODS 
This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines. 
Search strategy and selection criteria 
Articles were identified via PubMed, EMBASE, and Cochrane Library bibliographic 
databases (see Appendix A for search strategy). No restrictions were placed on language or 
publication date. The searches and data extractions were completed independently by two 
authors until March 19, 2020. Any disagreement in the literature screening or data extraction was 
resolved through discussion. We included comparative RCTs evaluating safety in adults who 
received HCQ therapy versus placebo. RCTs that did not report specific adverse events (AEs) 
were excluded. 
Outcomes, data analysis, and risk of bias 
 The outcomes of interest were the frequency of AEs. Peto odd ratios (Peto ORs) with 
95% confidence intervals (CIs) were assessed using random-effects models, and heterogeneity 
(I2) was evaluated using Cochran’s Q test. We examined the study quality using the Cochrane 
risk of bias tool for RCTs (low, unclear, or high) [9]. We performed all analyses using the 
Comprehensive Meta-Analysis Version 3 software (Biostat, Englewood, NJ, USA). 
 
RESULTS 
Search results and study characteristics 
The search process identified 713 articles, and a total of nine RCTs [10-18] were 
included after screening by title/abstract followed by full text review (Figure 1). This meta-
analysis included a total of 916 patients. The characteristics of studies are summarized in Table 
    
 
1, and the study quality assessment is summarized in Table 2. Eight RCTs were double-blind 
[11-18], and one was single-blind [10]. Only three RCTs were funded by drug companies [11, 
12, 18]. Studies were conducted on four different continents and included patients with a variety 
of indications. The average age of patients was over 60 years in only one study [17]. The 
duration of therapy was ≥12 weeks and the HCQ daily dose ranged between 200 and 400 
mg/day, except in one study, in which 800 mg/day was also used [13].  
 
Study outcomes 
Skin pigmentation occurred significantly more with HCQ than with placebo (Peto OR, 
4.64; 95% CI, 1.13 to 19.00; P-value=0.033; I2=0%) [Figure 1]. Although there was a numerical 
increase in the rate of AEs, no statistically significant differences were observed in the rate of 
rash  (Peto OR, 1.11; 95% CI, 0.3 to 3.77; P-value=0.03; I2=0%), gastrointestinal AEs (Peto OR, 
1.43; 95% CI, 0.55 to 3.72; P-value=0.46; I2=15.17%), headache (Peto OR, 1.94; 95% CI, 0.65 
to 5.78; P-value=0.23; I2=9.99%), dizziness (Peto OR, 1.32; 95% CI, 0.49 to 3.52; P-value=0.58; 
I2=0%), fatigue (Peto OR, 2.13; 95% CI, 0.76 to 5.98; P-value=0.15; I2=0%), or visual AEs (Peto 
OR, 1.61; 95% CI, 0.76 to 3.41; P-value=0.22; I2=0%) [Figures S1-6 in Appendix A]. No cardiac 
toxicity was reported in the studies. 
 
DISCUSSION 
 In this study, we evaluated the AEs of long-term use of HCQ, as the use of HCQ had 
been increasing recently with the current COVID-19 pandemics. In this meta-analysis, we 
attempted to examine systemic AEs of HCQ based on data from RCTs. To the best of our 
knowledge, this meta-analysis is the first attempt to examine such AEs in RCTs. One strength in 
this meta-analysis results is the low statistical heterogeneity as measured by I2, which indicates 
low variability in the effects of intervention being assessed in the different studies. However, it is 
important to consider that meta-analyses of AEs have some general pitfalls [19]. Therefore, the 
findings of this meta-analysis should be interpreted with caution. 
Of all screened studies, we included 9 RCTs. The included studies were mainly in 
relation to autoimmune diseases and were superiority studies. In addition, the daily dose of HCQ 
daily was 200 – 400 mg/day. The current use of HCQ in COVID-19 is mainly short term, and 
thus the observed AEs in this study might not occur in patients with COVID-19. We observed no 
significant increase in the occurrence of visual AEs.  However, retinopathy was considered an 
important AE in long-term users [20].   
An important observation in this meta-analysis is the occurrence of skin pigmentation 
significantly more with HCQ than with placebo. We cannot rule out the possibility of insufficient 
statistical power to detect statistically significant differences in other AEs. However, we included 
as many studies as we can by not limiting the inclusion criteria to specific indication to catch all 
studies reporting AEs of HCQ. Skin darkening is an important AE and potentially a cosmetic 
problem, as complete resolution is rare. The incidence of HCQ-related skin pigmentation was 
reported to be 7% in in patients with SLE and was not dose or duration dependent [21]. 
However, in one study the occurrence of skin pigmentation occurred after a median duration of 
32 months and a median cumulative dose of 361 g [22]. Since this AE may not occur in some 
patients receiving HCQ for short duration and the included studies used it for several weeks, it 
might not be relevant in the context COVID-19 except when used for a prolonged period in 
prophylaxis, which is currently being investigated [8]. Although the mechanism of development 
of skin pigmentation is not well characterized, one study indicated that a possible mechanism is 
    
 
the presence of both melanin and hemosiderin in the dermis [23]. In addition, a previous study 
identified multiple risk factors, such as bruising, the use of specific medications (corticosteroid, 
oral anticoagulants, antiplatelet agents), and the presence of antiphospholipid syndrome [20]. 
The distribution of skin pigmentation is variable and may involve lower extremities, the face, 
lips, and the gums [22] and may be in the form of a butterfly [24].   
 This meta-analysis showed no significant difference in the occurrence of skin rash with 
HCQ. The occurrence of skin rashes may be a characteristic of the underlying disease. In one 
study, the occurrence of skin rash was more common in patients who had dermatomyositis 
(31%) compared to those with cutaneous lupus erythematosus (3%) [25]. Skin rash was also 
common in patients with psoriasis and psoriatic arthritis [26]. The included studies in this meta-
analysis did not include patients with these underlying diagnoses. 
The occurrence of prolonged QTc interval was described in patients receiving HCQ, and 
discontinuation of HCQ shortened the QTc interval [27, 28]. Another potential cardiotoxicity is 
the occurrence of cardiomyopathy, and this was linked to older age, female gender, >10 years of 
therapy, high daily dose, and underlying cardiac disease and renal disease [29]. However, the 
occurrence of QT prolongation and cardiomyopathy were not reported in the included studies. 
There is concern about arrhythmias in patients with rheumatoid diseases treated with HCQ [30]. 
However, the included studies did not report on the occurrence of arrhythmias. Indeed, the 
references to cardiac toxicity included hydroxychloroquine overdoses or suicide attempts. 
Unfortunately, hydroxychloroquine and chloroquine in particular, are known to have been 
widely used in suicide attempts. Additionally, and because HCQ could prolong QTc, caution and 
ECG monitoring are required when using it, particularly in combination with other QTc-
prolonging medications [2, 7]. 
    
 
 Chloroquine and HCQ are metabolized by the hepatic cytochrome P450 enzyme 2D6 
(CYP2D6). CYP2D6 expression is variable depending on genetic polymorphisms, and 7% of 
white North Americans have no functional CYP2D6 “poor metabolizer” and 1–2% have gene 
duplications conferring an “ultrarapid metabolizer” phenotype. The variation in CYP2D6 may 
also influence the variability of AEs [30]. Glucose-6-phosphate dehydrogenase deficiency, which 
is associated with hemolysis after using some antimalarial drugs, seems to be of less concern 
with HCQ [31]. 
In conclusion, this meta-analysis showed that skin pigmentation was the only significant 
AE of HCQ compared to placebo. However, the included studies mainly evaluated the use of 
CHQ in the treatment of autoimmune diseases and did not include the full spectrum of these 
abnormalities. There are certain AEs that might be secondary to the underlying condition and 
might not be observed in other conditions. The use of HCQ in COVID-19 is an important new 
development for this drug, and further analysis is needed to specifically address AEs in this 
population as well as to establish the efficacy. 
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Figure 1 Flowchart of process of literature search and extraction of data from studies meeting the inclusion 
criteria. 
 
 
 
 
 
Records identified through 
database searching 
(n=713) 
- PubMed (n=78) 
- Embase (n=290) 
- Cochrane Library (n=345) 
Records screened 
(n=632) 
Records excluded 
based on title/abstract 
(n=617) 
Full-text articles assessed 
for eligibility 
(n=15) 
Full-text articles excluded (n=6) 
Reasons: 
- No specific adverse event 
reported (n=4) 
- Duplicate (n=2) Studies included in qualitative 
and quantitative synthesis (n=9) 
Duplicate records 
removed (n=81) 
    
 
Table 1. Characteristrics of included studies 
Study  Design Location Funding 
source  
Number 
of Patients 
Age (years) Indication Hydroxychloroquine 
Dose 
Duration 
of therapy 
(weeks) 
Boonpiyathad 
2017 [10] 
Superiority 
single-blind 
RCT 
1 site in 
Thailand 
Non-
industry 
48; 
24 vs. 24 
33 vs. 34 Chronic spontaneous 
urticaria 
400 mg/day 12 
Clark 1993 
[11] 
Superiority, 
double-
blind RCT 
1 site in 
Mexico 
Industry 121; 
63 vs. 58 
39 vs. 36 Rheumatoid arthritis 400 mg/day 24 
HERA Group 
1995 [12] 
Superiority, 
double-
blind RCT 
6 sites in 
Canada 
Industry 119; 
59 vs. 60 
53 vs. 53 Rheumatoid arthritis 200 mg/day, then 400 
mg/day after 2 weeks 
if tolerated  
36 
Kavanaugh 
1997 [13] 
Superiority, 
double-
blind RCT 
1 site in 
U.S. 
Non-
industry 
17; 
12 vs. 5 
Not available Systemic lupus 
erythematosus 
400 mg and 800 
mg/day 
12 
Lee 2018 [14] Superiority, 
double-
blind RCT 
6 sites in 
Netherlands 
Non-
industry 
196; 
98 vs. 98 
58 vs. 58 Osteoarthritis 400 mg q24h 24 
Liu 2019 [15] Superiority, 
double-
blind RCT 
1 site 
Finland 
Non-
industry 
60; 
30 vs. 30 
38 vs. 36 IgA nephropathy 200 mg q12h 24 
Paton 2012 
[16] 
Superiority, 
double-
blind RCT 
10 sites in 
U.K. 
Non-
industry 
83; 
42 vs. 41 
37 vs. 38 Asymptomatic HIV 
infection 
400 mg/day 48 
Van Gool 
2001 [17] 
Superiority, 
double-
blind RCT 
4 sites in 
Netherlands 
Non-
industry 
169; 
83 vs. 86 
70 vs. 71 Alzheimer’s disease 200 mg and 400 
mg/day 
72 
Yokogawa 
2017 [18] 
Superiority, 
double-
blind RCT 
22 sites in 
Japan 
Industry 103; 
77 vs. 26 
43 vs. 43 Cutaneous lupus 
erythematosus 
200 mg and 400 
mg/day 
16 
 
 
 
 
 
 
 
 
 
Table II. Quality assessment of included studies. 
Selection bias 
Performance 
bias 
Detection 
bias 
Attrition 
bias 
Reporting 
bias 
Other 
bias 
Study 
Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and 
personnel 
Blinding of 
outcome 
assessment
Incomplete 
outcome 
data 
Selective 
reporting 
Other 
bias 
Boonpiyathad 
2017 ? + - - + + + 
Clark 1993 ? ? + + + + ? 
HERA Group 
1995 + + + + + + ? 
Kravvariti 
2020 + + - - + - + 
Lee 2018 ? + + + + + + 
Liu 2019 + + + + + + + 
Paton 2012 + + + + + - + 
Van Gool 
2001 + + + + + + + 
Yokogawa 
2017 + + + + + - ? 
+, low risk of bias; “?” Unclear risk of bias; “-” high risk of bias 
Figure 2 Forest plot showing the Peto odds ratios of skin pigmentation in patients receiving 
hydroxychloroquine versus placebo. Vertical line, "no difference" point between the 2 groups; horizontal 
line, 95% confidence interval; squares, Peto odds ratios; diamonds, pooled Peto odds ratios. 
